Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma.
Oral cancer
Real time PCR
miRNA
miRNA-21
Journal
Pakistan journal of medical sciences
ISSN: 1682-024X
Titre abrégé: Pak J Med Sci
Pays: Pakistan
ID NLM: 100913117
Informations de publication
Date de publication:
Historique:
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
7
9
2019
Statut:
ppublish
Résumé
The high-throughput analysis of circulating microRNAs (miRNAs) is an active area of biomarker research. The oral cancer remains a common cancer among Pakistani males that continues to present at an advance stage, thus exhibiting poor survival. MiRNA 21 (miR-21) is the most consistently over-expressed miRNA in different types of tumor tissues. However, information regarding expression of miR-21 in plasma remains to be resolved. Therefore, present study was designed to investigate if miR-21 was expressed in plasma of patients with oral cancer, and further explore its diagnostic and prognostic potential. Present study was conducted at Ziauddin University and Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN). Histologically confirmed cases of oral squamous cell carcinoma were recruited from Oncology Department of Ziauddin Hospital between 2013 and 2017. Controls were carefully selected after considering age, gender and socioeconomic condition. MiRNA was extracted and immediately reverse transcribed to cDNA. MiR-21 expression was evaluated using probes specifically designed for Real time quantitative polymerase chain reaction. A significant over expression of miRNA 21 was observed in histologically confirmed cases as compared to controls. The increased expression of miRNA 21 was also reported to be associated with tumor size, metastasis and local invasion (p<0.05). The expression of circulating miR-21 in plasma samples of oral cancer patients makes it a promising diagnostic and prognostic marker.
Sections du résumé
BACKGROUND & OBJECTIVE
OBJECTIVE
The high-throughput analysis of circulating microRNAs (miRNAs) is an active area of biomarker research. The oral cancer remains a common cancer among Pakistani males that continues to present at an advance stage, thus exhibiting poor survival. MiRNA 21 (miR-21) is the most consistently over-expressed miRNA in different types of tumor tissues. However, information regarding expression of miR-21 in plasma remains to be resolved. Therefore, present study was designed to investigate if miR-21 was expressed in plasma of patients with oral cancer, and further explore its diagnostic and prognostic potential.
METHODS
METHODS
Present study was conducted at Ziauddin University and Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN). Histologically confirmed cases of oral squamous cell carcinoma were recruited from Oncology Department of Ziauddin Hospital between 2013 and 2017. Controls were carefully selected after considering age, gender and socioeconomic condition. MiRNA was extracted and immediately reverse transcribed to cDNA. MiR-21 expression was evaluated using probes specifically designed for Real time quantitative polymerase chain reaction.
RESULTS
RESULTS
A significant over expression of miRNA 21 was observed in histologically confirmed cases as compared to controls. The increased expression of miRNA 21 was also reported to be associated with tumor size, metastasis and local invasion (p<0.05).
CONCLUSION
CONCLUSIONS
The expression of circulating miR-21 in plasma samples of oral cancer patients makes it a promising diagnostic and prognostic marker.
Identifiants
pubmed: 31489016
doi: 10.12669/pjms.35.5.331
pii: PJMS-35-1408
pmc: PMC6717445
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1408-1412Déclaration de conflit d'intérêts
Conflict of interest: None.
Références
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10144-9
pubmed: 21646541
Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S103-9
pubmed: 22443195
Int J Oncol. 2012 Dec;41(6):1897-912
pubmed: 23026890
Chin J Cancer Res. 2011 Jun;23(2):123-8
pubmed: 23483517
Anticancer Res. 2013 Apr;33(4):1511-7
pubmed: 23564792
Oncol Rep. 2014 Mar;31(3):1429-36
pubmed: 24452363
PLoS One. 2014 Apr 22;9(4):e95193
pubmed: 24755828
PLoS One. 2014 Aug 01;9(8):e103698
pubmed: 25084400
PLoS One. 2016 Jul 21;11(7):e0159693
pubmed: 27441818
Microrna. 2016;5(3):175-179
pubmed: 27739364
Oncotarget. 2017 Feb 7;8(6):9911-9921
pubmed: 28039483
Asian Pac J Trop Med. 2017 Jan;10(1):87-91
pubmed: 28107872